Alzheimer's disease (AD) research has entered a new era with the recent positive phase 3
clinical trials of the anti-Aβ antibodies lecanemab and donanemab. Why did it take 30 years …

For many years Alzheimer's disease (AD) was associated with the dementia stage of the
disease, the tail end of a pathophysiological process that lasts approximately two decades …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Alzheimer's disease (AD) is the leading cause of dementia in older adults. Although AD
progression is characterized by stereotyped accumulation of proteinopathies, the affected …

Importance The recent proliferation of phosphorylated tau (p-tau) biomarkers has raised
questions about their preferential association with the hallmark pathologies of Alzheimer …

Staging the severity of Alzheimer's disease pathology using biomarkers is useful for
therapeutic trials and clinical prognosis. Disease staging with amyloid and tau PET has face …

Recent mechanistic and structural studies have challenged the classical tauopathy
classification approach and revealed the complexity and heterogeneity of tau pathology in …

Recently approved anti-amyloid immunotherapies for Alzheimer's disease (AD) require
evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal …

This work aimed to investigate potential pathways linking age and imaging measures to
early age-and pathology-related changes in cognition. We used [18F]-Flutemetamol …

Abstract Positron Emission Tomography (PET) ligands have advanced Alzheimer's disease
(AD) diagnosis and treatment. Using autoradiography and cryo-EM, we identify AD brain …